March 2005
Sun Mon Tue Wed Thu Fri Sat
    1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31    
Feb   Apr


For more search options, please see the Advanced search form and the section of the User's Guide, Tips for Searching PULSE.


C H A N N E L S
• PULSE Home Page
• EXECUTIVE EDITION

• US News
• Canada News
• UK News
• New Zealand News

• Consumer Advocacy
• Health Care Systems
• Managed Care/Medicaid
• Co-occurring Disorders
• Clinical studies
• Pharmaceutical News
• Criminal Justice Systems
• Legislative News


U S E R ' S   G U I D E
About PULSE
PULSE Channels
Archives
Adding comments
Using the # link
Items that require registration
PULSE syndication
Tips for Searching PULSE


E M A I L   S U B S C R I P T I O N S

For WEEKLY summaries of PULSE postings, see the weekly email subscription form.

For DAILY mailings (powered by Bloglet), please enter your e-mail address below:


P U B L I C A T I O N S

PULSE ANNUAL No. 2
January 2003

Recent Trends, Challenges and Issues in Funding Public Mental Health Services in the US
March 2002

PULSE ANNUAL No. 1
October 2001

 

PULSE is powered by
Radio Userland.

Listed on BlogShares

© Bill Davis, 2000-2003.

About PULSE | Channels | User's Guide | Email subscriptions | Publications




PULSE is a free service of the Centre for Community Change International, gathering new and noteworthy Internet resources for mental health providers, family members of individuals with mental illness, consumers of mental health services and consumer advocates. PULSE is researched, edited and designed by Bill Davis.



daily link  Friday, March 04, 2005


FDA Seizes Glaxo's Paxil Reuters story at Yahoo - "The U.S. Food and Drug Administration said on Friday that officials had seized batches of GlaxoSmithKline Plc's diabetes drug Avandamet and the controlled-release antidepressant Paxil CR because of concerns over manufacturing quality. The FDA  said in a statement that the manufacturing practices for the two drugs failed to meet standards for safety, strength, quality and purity. However, the agency said it was not aware of any harm to consumers and did not believe there was a significant health hazard. Patients taking the two drugs were advised to continue taking their medication but talk to their doctor about possibly using alternative products until the manufacturing problems have been corrected. "  
permalink